The FDA authorized teprotumumab (Tepezza) in 2020 for the treatment of grownups with thyroid eye illness (TED). The drug is an insulin-like development factor-1 receptor inhibitor (IGF-1R), completely humanized monoclonal antibody produced in Chinese hamster ovary (CHO-DG44) cells, with a molecular weight of ~ 148 kilodaltons. 1
Through clinical advances and the essential research studies performed by numerous scientists around the globe, there has actually been a much better understanding of the pathophysiology of TED and autoimmune illness. Biologic treatments have actually moved the focus in dealing with TED, 3 making teprotumumab an unique and distinct restorative method in the treatment of TED.
Presently, it is the only FDA-approved medication readily available for TED and its signs. It reveals guarantee compared to the conventional methods of offering supplements or vitamins, steroids, and surgical treatment. These treatments stop the swelling however are frequently not sustainable. 3
Biologics, such as teprotumumab, have a much better security profile and effectiveness due to the fact that they have the benefit in targeted restorative alternatives, which caused the accurate immune modulation. For that reason, this represents a much better alternative treatment choice for a specific niche group of individuals with TED.
TED is a complicated illness related to progressive autoimmune illness that takes place when the body’s body immune system assaults the tissue behind the eyes, which results in swelling of the eyes. The swollen tissues press forward and trigger the eyes to bulge (proptosis).
This avoids the eyelids from entirely closing, showing signs such as dry eyes, gritty eyes, watery eyes, fuzzy vision, eye discomfort, and double vision (diplopia). Not just is it aesthetically hindering, however likewise facially disfiguring, which has an unfavorable and considerable influence on the lifestyle for the client.
When TED is left unattended, it might increase the threat of permanent nerve damage and vision loss. For that reason, it is essential to deal with TED as early as possible to avoid more eye damage and unfavorable long-lasting impacts on illness results. 4
Teprotumumab has actually been discovered to be safe and extremely efficient in decreasing proptosis, diplopia, and enhancing lifestyle after 24 weeks treatment.
System of action
Teprotumumab’s system of action in clients with TED has actually not been completely identified. IGF-1R are cell receptors discovered on the surface area of the tissue on the back of the eyes.
These receptors imitate switches– in typical eyes these switches are “shut off.” Nevertheless, in clients with TED, the switches are triggered by the body’s own immune cells, and “switching on” results in swelling and swelling of the regional tissue, triggering proptosis, discomfort, and diplopia of the eyes.
In the treatment of teprotumumab, the discussion of the monoclonal antibodies binds to IGF-1R and obstructs its activation and downstream signaling path. 1 For that reason, it decreases swelling, which leads to the decrease of symptoms and signs such as proptosis, discomforts, and diplopia.
Dosing and administration
Teprotumumab is supervised by means of systemic intravenous (IV) infusion, readily available in 500 mg lyophilized powder in a single-dose vial for reconstitution for injection. The preliminary dosage is 10 mg/kg IV infusion over 60 to 90 minutes and followed by 20 mg/kg every 3 weeks for 7 extra infusions. 1
Medical research studies
Teprotumumab, a monoclonal antibody inhibitor of IGF-1R has actually been studied in multicenter, double-masked, placebo-controlled medical trials showed to minimize eye bulging, enhance double vision, supply remedy for eye discomforts, inflammation, swelling, enhance visual capability, physical look, and much better lifestyle. 2
Contraindications and cautions
Teprotumumab might trigger infusion responses, according to the medical research studies, infusion responses have actually been reported in roughly 4% of clients. Infusion responses can occur throughout the treatment, or within 24 hr after the treatment is finished.
Symptoms and signs of infusion are hypertension, quick heart beat, inflammation of the face or sensation hot, trouble breathing, headache, and muscle discomfort. 1
Preventative measures have actually been determined in clients with preexisting inflammatory bowel illness (IBD) and diabetes. Teprotumumab might trigger a worsening of preexisting IBD. In medical trials, 10% of clients with preexisting diabetes experienced hyperglycemia. 1
Usage in unique population
Pregnant or Breast feeding females: Well-controlled research studies of teprotumumab in pregnant females have actually not been performed and there are inadequate information for the security of using teprotumumab in this population. In-utero teprotumumab direct exposure of cynomolgus monkeys led to external and skeletal irregularities. For that reason, teprotumumab needs to not be utilized in pregnancy due to the threat of damaging the coming child. It is not understood if teprotumumab enters breast milk, for that reason not suggested for nursing female. 1
Pediatric: The security and effectiveness of teprotumumab has actually not been assessed in clients less than 18 years of age.
Geriatric: There is no distinction in security and effectiveness in clients 65 years of age and older.
Negative occasions (AEs)
Infusion response, worsening of pre-existing IBD, and hyperglycemia are medically substantial AEs that has actually been explained cautioning and safety measures. 1
In the medical trials, the AEs of clients taking place in 5% or more who were treated with teprotumumab are muscle convulsions, queasiness, alopecia, diarrhea, tiredness, hyperglycemia, hearing problems, dysgeusia, headache, and dry skin. 1
Last but not least, all biologic therapies have the prospective to trigger immune reactivity. 1
Carcinogenesis, mutagenesis, and problems of fertility have actually not been assessed. 1
Storage and handling
Shop in fridge at 2 ͦC to 8 ͦC (36 ͦF to 46 ͦF) in initial container up until time of usage. Secure from light. Do not freeze. 1
About the Author
Steffanie Ung is a PharmD prospect at Marshall B. Ketchum University College of Drug store, expected to finish in spring 2023. She finished this short article while on a specialized pharmacy-focused virtual Advanced Drug store Practice Rotation at STACK. For additional information about STACK, or to ask about APPE rotations, go to www.managewithstack.com.
- TEPEZZA ® (bundle insert). Deerfield, IL: Horizon Rehabs U.S.A., Inc; 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e6c54a1-cefd-4a5b-a855-ab9f268b6cce
- Horizon Pharma U.S.A., Inc. Treatment of Graves ‘Orbitopathy (Thyroid Eye Illness) to Decrease Proptosis with Teprotumumab infusions in a Randomized, Placebo-Controlled, Medical Research Study (OPTIC). https://www.clinicaltrials.gov/ct2/show/study/NCT03298867?term=teprotumumab&draw=2&rank=3. Accessed October 1, 2022
- Male CJ, Kossler AL, Wester ST. Updates on the understanding and management of thyroid eye illness. Ther Adv Ophthalmol.2021 Jun 30; 13:25158414211027760. PMID: 34263138; PMCID: PMC8252358
- Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, Kahaly GJ, Ludgate M. New insights into the pathogenesis and nonsurgical management of Tomb orbitopathy. Nat Rev Endocrinol. 2020 Feb; 16( 2 ):104 -116. Doi:10.1038/ s41574-019-0305-4. Epub 2019 Dec 30. PMID: 31889140.